Onco-hematology
Review | Diagnosis and treatment of myelodysplastic syndromes.
7 Sep, 2022 | 12:33h | UTCDiagnosis and Treatment of Myelodysplastic Syndromes: A Review – JAMA (free for a limited period)
Audio Clinical Review: Diagnosis and Management of Myelodysplastic Syndromes – JAMA
Cohort Study | Clinical and molecular determinants of clonal evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria.
7 Sep, 2022 | 12:29h | UTCClinical and Molecular Determinants of Clonal Evolution in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter (thread – click for more)
Super excited to share our multicenter study on clonal evolution in 1008 patients with AA/PNH followed for a median f-up of 9 yrs now out in @JCO_ASCO https://t.co/j9U2ZjYX0o
— Carmelo Gurnari (@CarmeloGurnari) September 2, 2022
Long-term results of a RCT | Long-term outcomes for ibrutinib–rituximab and chemoimmunotherapy in chronic lymphocytic leukemia.
31 Aug, 2022 | 11:32h | UTCCommentary: Ibrutinib Plus Rituximab Yields Superior Survival Vs FCR in CLL, Regardless of IGHV Status – Cancer Network
Single-arm phase 2 study | Rituximab, Lenalidomide, and Ibrutinib in patients with newly diagnosed Large B-Cell Lymphoma.
26 Aug, 2022 | 13:05h | UTCSmart Start: Rituximab, Lenalidomide, and Ibrutinib in Patients With Newly Diagnosed Large B-Cell Lymphoma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
In a phase II study in 60 pts with newly diagnosed DLBCL, the ORR after 2 cycles of rituximab, lenalidomide & ibrutinib was 86.2%, with a CR rate of 94.5% after a further 6 cycles together with standard chemo; 2-yr PFS & OS were 91.3% & 96.6%, respectively https://t.co/lvNs8DFSYp
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
Long-term results of a RCT | Lenalidomide plus Rituximab vs. Rituximab-chemotherapy followed by Rituximab maintenance in untreated advanced Follicular Lymphoma.
26 Aug, 2022 | 13:03h | UTCCommentaries:
Commentary on Twitter
6-year update from the phase III RELEVANCE trial of lenalidomide-rituximab versus rituximab-chemotherapy in previously untreated patients with advanced-stage follicular lymphoma demonstrates very similar durable efficacy and safety: https://t.co/rMeA2tOoO6 #lymsm #hemeonc
— NatureRevClinOncol (@NatRevClinOncol) August 19, 2022
M-A | Interventions to reduce infections in patients with hematological malignancies.
15 Aug, 2022 | 11:51h | UTCCommentary: Prophylactic Immunoglobulin, Vaccinations May Reduce Infections in Hematologic Malignancies – AJMC
Long-term results of a phase 2 RCT | Elotuzumab plus pomalidomide and dexamethasone for relapsed/refractory multiple myeloma.
15 Aug, 2022 | 11:46h | UTCOriginal Study: Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma – New England Journal of Medicine
RCT | Low-dose Decitabine vs. low-dose Azacitidine in lower-risk myelodysplastic syndromes.
11 Aug, 2022 | 12:04h | UTCLow-Dose Decitabine versus Low-Dose Azacitidine in Lower-Risk MDS – NEJM Evidence
Commentary on Twitter
Low dose hypomethylating agent therapy led to an overall response rate of 60% in pts with low- or intermediate-risk myelodysplastic syndromes or chronic myelomonocytic leukemia who had not received prior hypomethylating agents. https://t.co/OSpNLzfiKW#MDS #LeuSM #CMML pic.twitter.com/BN1XAhfUBo
— NEJM Evidence (@NEJMEvidence) August 9, 2022
Single-arm phase 2 study | Long-term follow-up of combination of B-Cell maturation antigen and CD19 chimeric antigen receptor T cells in multiple myeloma.
9 Aug, 2022 | 12:22h | UTCLong-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary on Twitter
🙌 Combination of anti-BCMA and anti-CD19 CAR T cells induced durable response in patients with relapsed/refractory #MultipleMyeloma ➡️ https://t.co/TkPRcTKSxg #JCO #MMSM pic.twitter.com/0OZAJtTXF1
— Journal of Clinical Oncology (@JCO_ASCO) April 15, 2022
Guideline | Management of antithrombotic treatments in thrombocytopenic patients with cancer.
5 Aug, 2022 | 14:37h | UTC
Single-arm phase 1b study | Venetoclax Plus Gilteritinib for FLT3-mutated relapsed/refractory acute myeloid leukemia.
1 Aug, 2022 | 11:46h | UTC
Commentary on Twitter
🙌 Venetoclax plus gilteritinib yields modified composite complete response of 75% in FLT3-mutated relapsed/refractory #AcuteMyeloidLeukemia
Read in #JCO ➡️ https://t.co/L7wxJ63qv9 #AML #leusm @Daver_Leukemia @jaltmanmd pic.twitter.com/ksXw1DNMsE
— Journal of Clinical Oncology (@JCO_ASCO) July 29, 2022
RCT | Short vs. extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia.
27 Jul, 2022 | 12:17h | UTCShort versus extended treatment with a carbapenem in patients with high-risk fever of unknown origin during neutropenia: a non-inferiority, open-label, multicentre, randomised trial – The Lancet Haematology (link to abstract – $ for full-text)
Commentary: Short-Course or Extended Antibiotics in Febrile Neutropenia? – Medscape (free registration required)
Commentary on Twitter
NEW online—Short-term is not inferior to extended carbapenem in patients with haematological malignancy and neutropenic fever of unknown origin, however, higher serious adverse events and mortality were noted in the short treatment group: the SHORT trial https://t.co/FOp1M3D6cL pic.twitter.com/6z5e8MSEgQ
— The Lancet Haematology (@TheLancetHaem) June 10, 2022
Cohort Study | Long-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors.
27 Jul, 2022 | 11:53h | UTCLong-term risk of cardiovascular disease mortality among classic Hodgkin lymphoma survivors – Cancer
Commentaries:
CVD Mortality Leading Cause of Death for Stage I, II Hodgkin Lymphoma – HealthDay
RCT | Enasidenib vs. conventional care in mutant-IDH2 relapsed/refractory acute myeloid leukemia.
22 Jul, 2022 | 11:31h | UTC
The epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends.
20 Jul, 2022 | 12:08h | UTCThe epidemiological landscape of multiple myeloma: a global cancer registry estimate of disease burden, risk factors, and temporal trends – The Lancet Haematology (free registration required)
Commentary on Twitter (thread – click for more)
@CUHKMedicine: collaborative work with @APRU1997 colleagues published. @TheLancet Haematology: Epidemiological Landscape of Multiple Myeloma from Cancer Registry Analysis @CUHKGlobal pic.twitter.com/17tr2Z30Xh
— Wong Chi Sang Martin (@drwong_martin) July 14, 2022
Single-arm phase 2 study | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma.
20 Jul, 2022 | 11:37h | UTCSafety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
ELN International Recommendations for the diagnosis and management of acute myeloid leukemia in adults.
19 Jul, 2022 | 13:28h | UTC
Single arm phase 2 study | Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for hematopoietic stem cell transplantation.
19 Jul, 2022 | 13:00h | UTCLisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Second-Line CAR-T Impresses in Transplant-Ineligible Large B-Cell Lymphoma – MedPage Today (free registration required)
Related:
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study – The Lancet (link to abstract – $ for full-text)
Commentary on Twitter
Online first: #Lisocabtagene maraleucel as second-line therapy in adults with R/R large B-cell #lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study https://t.co/NwkfPmVHu0 #lymsm pic.twitter.com/jHj5rFadV2
— The Lancet Oncology (@TheLancetOncol) July 13, 2022
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
19 Jul, 2022 | 12:57h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)
Commentary: Zanubrutinib Wins in First-Line CLL for Older Patients — The BTK inhibitor proves superior to bendamustine-rituximab in phase III trial – MedPage Today (free registration required)
RCT | Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin’s lymphoma.
18 Jul, 2022 | 11:13h | UTCOverall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma – New England Journal of Medicine (link to abstract – $ for full-text)
News Release: Brentuximab vedotin may improve overall survival in patients with Hodgkin Lymphoma – Mayo Clinic
The EBMT nursing guidelines on CAR-T Therapy | A framework for patient care and managing common toxicities.
14 Jul, 2022 | 12:45h | UTC
Review | Cardiovascular disease in myeloproliferative neoplasms.
14 Jul, 2022 | 12:38h | UTC
Single-arm study | Long-term benefits of Tagraxofusp for patients with blastic plasmacytoid dendritic cell neoplasm.
14 Jul, 2022 | 12:13h | UTCRelated Study: Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm – New England Journal of Medicine
RCT | Neutropenic versus regular diet for acute leukemia induction chemotherapy.
13 Jul, 2022 | 11:45h | UTCNeutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)
Related:
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancer – European Journal of Cancer (link to abstract – $ for full-text)
Neutropenic diets to prevent cancer infections: updated systematic review and meta-analysis – BMJ Supportive & Palliative Care (link to abstract – $ for full-text)
Things We Do For No Reason: Neutropenic Diet – Journal of Hospital Medicine (PDF)
RCT | Zanubrutinib vs. bendamustine and rituximab in untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.
11 Jul, 2022 | 11:49h | UTCZanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial – The Lancet Oncology (link to abstract – $ for full-text)